GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BeiGene Ltd (HKSE:06160) » Definitions » Gross Margin %

BeiGene (HKSE:06160) Gross Margin % : 82.98% (As of Sep. 2024)


View and export this data going back to 2018. Start your Free Trial

What is BeiGene Gross Margin %?

Gross Margin % is calculated as gross profit divided by its revenue. BeiGene's Gross Profit for the three months ended in Sep. 2024 was HK$6,475 Mil. BeiGene's Revenue for the three months ended in Sep. 2024 was HK$7,803 Mil. Therefore, BeiGene's Gross Margin % for the quarter that ended in Sep. 2024 was 82.98%.


The historical rank and industry rank for BeiGene's Gross Margin % or its related term are showing as below:

HKSE:06160' s Gross Margin % Range Over the Past 10 Years
Min: -67.72   Med: 83.97   Max: 97.91
Current: 83.74


During the past 11 years, the highest Gross Margin % of BeiGene was 97.91%. The lowest was -67.72%. And the median was 83.97%.

HKSE:06160's Gross Margin % is ranked better than
79.49% of 746 companies
in the Biotechnology industry
Industry Median: 60.565 vs HKSE:06160: 83.74

BeiGene had a gross margin of 82.98% for the quarter that ended in Sep. 2024 => Durable competitive advantage

The 5-Year average Growth Rate of Gross Margin for BeiGene was -0.20% per year.


BeiGene Gross Margin % Historical Data

The historical data trend for BeiGene's Gross Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BeiGene Gross Margin % Chart

BeiGene Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Gross Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 83.38 77.12 85.98 79.77 84.55

BeiGene Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Gross Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 87.67 83.32 83.38 85.13 82.98

Competitive Comparison of BeiGene's Gross Margin %

For the Biotechnology subindustry, BeiGene's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BeiGene's Gross Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BeiGene's Gross Margin % distribution charts can be found below:

* The bar in red indicates where BeiGene's Gross Margin % falls into.



BeiGene Gross Margin % Calculation

Gross Margin is the percentage of Gross Profit out of sales or Revenue.

BeiGene's Gross Margin for the fiscal year that ended in Dec. 2023 is calculated as

Gross Margin % (A: Dec. 2023 )=Gross Profit (A: Dec. 2023 ) / Revenue (A: Dec. 2023 )
=16235.5 / 19202.572
=(Revenue - Cost of Goods Sold) / Revenue
=(19202.572 - 2967.099) / 19202.572
=84.55 %

BeiGene's Gross Margin for the quarter that ended in Sep. 2024 is calculated as


Gross Margin % (Q: Sep. 2024 )=Gross Profit (Q: Sep. 2024 ) / Revenue (Q: Sep. 2024 )
=6475.4 / 7803.458
=(Revenue - Cost of Goods Sold) / Revenue
=(7803.458 - 1328.07) / 7803.458
=82.98 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


BeiGene  (HKSE:06160) Gross Margin % Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

BeiGene had a gross margin of 82.98% for the quarter that ended in Sep. 2024 => Durable competitive advantage


Be Aware

If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.


BeiGene Gross Margin % Related Terms

Thank you for viewing the detailed overview of BeiGene's Gross Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


BeiGene Business Description

Address
c/o Mourant Governance Services (Cayman) Limited, 94 Solaris Avenue, Camana Bay, Grand Cayman, CYM, KY1-1108
Founded in 2010 in Beijing and having listed on the Hong Kong exchange in 2018, BeiGene is a commercial-stage biotechnology company with global sales. It focuses on oncology therapeutics and differentiates itself from other companies with a contract research organization-free, or CRO-free strategy. BeiGene runs global clinical trials with its own team. As of 2023, its core drug is Brukinsa, a small molecule drug for various blood cancers that makes up more than 50% of BeiGene's revenue.
Executives
Oyler John Victor 2101 Beneficial owner
Jpmorgan Chase & Co. 2502 Approved lending agent
The Capital Group Companies, Inc. 2201 Interest of corporation controlled by you
Baker Felix James 2201 Interest of corporation controlled by you
Baker Julian Charles 2201 Interest of corporation controlled by you
Baker Bros. Advisors (gp) Llc 2201 Interest of corporation controlled by you
Baker Brothers Life Sciences Capital, L.p. 2201 Interest of corporation controlled by you
Hhlr Advisors, Ltd. 2102 Investment manager
Hhlr Fund, L.p. 2101 Beneficial owner
Amgen Inc. 2101 Beneficial owner
Hillhouse Capital Advisors, Ltd. 2102 Investment manager
Gaoling Fund, L.p. 2101 Beneficial owner
Fidelity Management & Research Company
Fmr Co., Inc.

BeiGene Headlines

No Headlines